[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
Pascal Grondin, Arnaud François, Anne-Pascale Luzy, Cedric Vinson, Yann Lamotte, Petra Blom, Arnaud Le Tiran, Laurence Danober, Johannes Krupp, Jan Hoflack and Nicolas Ancellin
Strong genetic evidence has validated Leucine-Rich Repeat Kinase 2 (LRRK2) as a target of interest for Parkinson’s Disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent and selective LRRK2 inhibitor. This poster presents the in vitro pharmacological profile of Compound A.
Prepared in collaboration with Servier
Please see the accompanying poster for the in vivo PK/PD profile of Compound A